More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Telix and AusHealth Partner for Lung, Ovarian Cancer

Oct 29, 2019 at 9:34 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Oct 29, 2019 at 9:34 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/telix-and-aushealth-partner-for-lung-ovarian-cancer

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • Appendix 4C - September 2019 quarterOct 28, 2019
  • Telix to Acquire European Production FacilityOct 2, 2019
  • FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumetAug 27, 2019
  • Appendix 4D and Financial Report for half-year to 30 June 19Aug 22, 2019
  • First Australian Patient Dosed in ZIRCON Phase III TrialAug 20, 2019

Later from Telix Pharmaceuticals

  • Telix and ATONCO Partner for Bladder CancerDec 15, 2019
  • Telix and Vic Cancer Centre receive Cancer Australia grantDec 19, 2019
  • Zircon P3 IND submitted to US FDADec 23, 2019
  • NDA Clinical Briefing Package Submitted to the US FDADec 26, 2019
  • Telix Granted FDA Approval for ZIRCON Renal Cancer ImagingJan 22, 2020
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer